Prosecution Insights
Prosecution Insights
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (57%) |
| §102 only | 1 (14%) |
| No statute on record | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 1 | 73.2% | +24.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.2% |
| DEKARSKE, MADELINE MCGUIRE | 1 | — | — |
| CHAO, ALLEN | 1 | 100.0% | +0.0% |
| RAO, PADMAJA S | 1 | 69.5% | +35.9% |
| SIMS, JASON M | 1 | 44.4% | +21.5% |
| SIMMONS, CHRIS E | 1 | 34.6% | +19.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18337253 | LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION | CHAO, ALLEN | 42d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17518846 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | SIMMONS, CHRIS E | 112d overdue |
| 17839374 | SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION | SIMS, JASON M | 56d overdue |
| 18325655 | R-MDMA CRYSTAL FORMS | RAO, PADMAJA S | 4d overdue |
| 18421264 | R-MDMA FOR TREATMENT OF PAIN | ANDERSON, REBECCA L | 13d |
| 18543789 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | CHANDRAKUMAR, NIZAL S | 15d |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1626 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421264 | R-MDMA FOR TREATMENT OF PAIN | ANDERSON, REBECCA L | 1626 | §102 | Non-Final OA | 13d | Pending | Jan 24, 2024 |
| 18543789 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 15d | Pending | Dec 18, 2023 |
| 18344584 | METHODS OF MANUFACTURE OF R-MDMA | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Final Rejection | 12d | Pending | Jun 29, 2023 |
| 18337253 | LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION | CHAO, ALLEN | 1622 | §103 | Non-Final OA | 42d | Pending | Jun 19, 2023 |
| 18325655 | R-MDMA CRYSTAL FORMS | RAO, PADMAJA S | 1627 | Other | Non-Final OA | 4d overdue | Pending | May 30, 2023 |
| 17839374 | SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION | SIMS, JASON M | 3791 | §103 | Non-Final OA | 56d overdue | Pending | Jun 13, 2022 |
| 17518846 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | SIMMONS, CHRIS E | 1622 | Other | Final Rejection | 112d overdue | Pending | Nov 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial